Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Medscape’s Virtual Patient Simulation Makes a Significant Impact on Real-World Treatment Selection for T2D

An analysis of data using Real-World Outcomes showed that a virtual patient simulation had a significant effect on real-world treatment selection for T2D. The paper, published in JMIR Medical Education,...

Medscape Education

Top 10 Most Important Advisor Questions: Messaging and Branding

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

Impetus Digital

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

UK rejoins Horizon Europe research initiative under new bespoke agreement

The UK will now participate as a fully associated member for the rest of the programme

- PMLiVE

Tonix’s long COVID drug fails to meet mid-stage trial primary endpoint

TNX-102 SL was shown to effectively improve fatigue symptoms in people with long COVID

- PMLiVE

Moderna’s updated COVID-19 vaccine shows strong effect against BA.2.86 subvariant

The ‘highly mutated’ BA.2.86 subvariant is being closely monitored by global health authorities

- PMLiVE

redthread market access appoints Victoria Thomas as head of strategic market access

Thomas joins the agency from health network company Havas M&C

- PMLiVE

A Rare Disease Update from Medscape Education

A Novel Provider Education Module to Enhance Detection of Alpha-1 Antitrypsin Deficiency

Medscape Education

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by MHRA

The updated vaccine proved effective against the currently circulating XBB.1.5 subvariant

- PMLiVE

MIT study finds drug candidate reduces inflammation in Alzheimer’s models

The candidate significantly reduced inflammation and improved cognitive functions

- PMLiVE

BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody

The company will gain exclusive rights to develop and commercialise obexelimab

- PMLiVE

Seagen and Genmab’s Tivdak shows promise in phase 3 cervical cancer trial

The drug received FDA accelerated approval in 2021 to treat patients with advanced disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links